Eledon Pharmaceuticals Inc Stock Price, News & Analysis

Eledon Pharmaceuticals, a clinical stage biopharmaceutical company, announced it will host its first R&D Day on April 28, 2022, from 10 a.m. to 12 p.m. ET. This virtual event will feature Eledon’s senior management team alongside leading experts discussing the investigational drug tegoprubart and the potential of CD40 Ligand targeted immunotherapy for conditions like ALS and kidney transplantation. The presentation will include insights from prominent professionals in neurology and renal medicine. For more details, visit the company's R&D Day website.

Eledon Pharmaceuticals (NASDAQ: ELDN) reported its fourth quarter and full-year 2021 results, marking a significant year of progress.

They fully enrolled a Phase 2a trial for tegoprubart in ALS and initiated multiple other clinical studies. The cash balance stands at $84.8 million, expected to fund operations into 2024.

Net losses were $34.5 million for 2021, up from $22.8 million in 2020, primarily due to increased R&D expenses.

Topline data from the ALS trial is expected in 2Q 2022.

Eledon Pharmaceuticals (NASDAQ: ELDN) will release its fourth quarter and full year 2021 financial results on March 24, 2022, after market close. The management team will host a conference call and webcast at 4:30 p.m. ET to discuss the results. Eledon focuses on developing innovative treatments for organ and cell transplantation, autoimmune diseases, and neurodegenerative disorders. Its lead product, tegoprubart, targets the CD40 Ligand pathway, offering potential benefits for patients requiring transplants or suffering from ALS.

Eledon Pharmaceuticals (NASDAQ: ELDN) announced the completion of enrollment for all cohorts in its Phase 2a study of tegoprubart in Amyotrophic Lateral Sclerosis (ALS). The company received USAN approval for the generic name tegoprubart for its lead asset AT-1501. With a robust capital position, Eledon is well-funded to support operations into 2024. Anticipated clinical data readouts in 2022 include topline results from the ALS trial and studies in kidney transplantation and IgA nephropathy. Eledon aims to advance precision therapies targeting the CD40 ligand pathway.

Eledon Pharmaceuticals (NASDAQ: ELDN), a clinical stage biopharmaceutical company, announced that its CEO, David-Alexandre C. Gros, M.D., will participate in a fireside chat at the 11th Annual SVB Leerink Virtual Global Healthcare Conference on February 17 at 5:00 p.m. EST. This event focuses on innovative treatments for organ and cell transplantation, autoimmune diseases, and neurodegenerative conditions. Interested participants can register for the webcast here.

Eledon Pharmaceuticals (NASDAQ: ELDN) announced participation in two virtual investor conferences. The LifeSci Partners Corporate Access Event will be held from January 5-7, 2022, featuring 1x1 meetings. The second event, H.C. Wainwright BIOCNNECT Virtual Conference, is scheduled for January 10-13, 2022 with available on-demand presentations and 1x1 meetings. Eledon focuses on developing treatments for organ transplantation, autoimmune diseases, and neurodegenerative conditions, led by its compound AT-1501, targeting the CD40 ligand pathway.

Eledon Pharmaceuticals (NASDAQ: ELDN) reported its Q3 2021 financial results, marking a net loss of $9.8 million or $0.66 per share, an increase from the previous year's loss of $6.1 million. The company is progressing with its AT-1501 treatment, nearing full enrollment in its Phase 2 ALS study and receiving FDA IND clearance for islet cell transplantation. A collaboration with CareDx was also announced to enhance renal transplantation research. With approximately $94 million in cash, Eledon is funded into 2023 and anticipates key clinical developments in the upcoming quarters.

Eledon Pharmaceuticals (NASDAQ: ELDN) announced a presentation by CEO David-Alexandre C. Gros on November 5, 2021, during the virtual Transplant Innovation Day hosted by CareDx. The focus will be on the investigational use of AT-1501 for kidney transplantation and its collaboration with CareDx to evaluate efficacy in preventing organ rejection. Eledon leverages CareDx’s advanced technologies, including the KidneyCare™ suite, to enhance data collection on allograft health as part of its clinical development efforts.

Eledon Pharmaceuticals (NASDAQ: ELDN) announced participation in two virtual investor conferences in November. The first is the Guggenheim 3rd Annual Neuro/Immunology Conference on November 15-16, followed by the Jefferies London Healthcare Conference on November 18-19, featuring available on-demand presentations. Eledon focuses on developing targeted therapies for autoimmune diseases and organ transplants, with its lead compound, AT-1501, an anti-CD40L antibody aimed at immune regulation and potentially superior safety and efficacy.